Differences between Clinical Features and White Matter Hyperintensities between Vascular Parkinsonism and Parkinson′s Disease

doi:10.3969/j.issn.1673-5765.2023.08.002

Abstract

Abstract: Objective The study of the differences in clinical features and white matter hyperintensities (WMH) between vascular parkinsonism (VP) and Parkinson’s disease (PD) can provide some basis and ideas for studying the pathogenesis of VP.
Methods According to the clinical practice, the number of healthy subjects was matched at a ratio of 1:2. VP patients meeting the inclusion criteria and PD patients and healthy volunteers matching their age, gender and education level were retrospectively screened, and healthy volunteers were selected as the healthy control (HC) group. Collected their general clinical data and biochemical indicators, evaluated the clinical symptoms of patients, collected head MRI parameters and made statistical analyses of the data of the three groups of subjects.
Results A total of 26 VP patients, 26 PD patients and 13 HC were enrolled in this study. Compared with the PD group, VP group had worse overall cognition and mental state: HAMA score was higher (P=0.025), MMSE score (P=0.001) and MoCA score (P=0.008) were lower; more vascular risk factors: a higher proportion of patients had a history of hypertension (P=0.012) and stroke (P<0.001); more severe white matter damage in motion-related brain regions: WMH total score (P<0.001), deep white matter hyperintensities (DWMH) total score (P=0.001), periventricular hyperintensities (PVH) total score (P=0.002), PVH scores in motion-related brain regions [frontal horn cap white matter hyperintensities score (P=0.002), lateral ventricular belt white matter hyperintensities score (P=0.018)], DWMH scores in motion-related brain regions [frontal deep white matter hyperintensities score (P<0.001), parietal deep white matter hyperintensities score (P=0.007)], basal ganglia white matter hyperintensities score (P=0.002), putamen white matter hyperintensities score (P=0.029) were higher. All were statistically significant (all P<0.05).
Conclusions A history of hypertension, a history of stroke, and white matter damage in motion-related brain regions may play an important role in the pathogenesis of VP.

Key words: Vascular parkinsonism; Parkinson′s disease; Clinical features; White matter hyperintensities

摘要： 目的研究血管性帕金森综合征（vascular parkinsonism，VP）与帕金森病（Parkinson’s disease，PD）临床特征及脑白质高信号（white matter hyperintensities，WMH）的差异，为研究VP的发病机制提供一定的依据与思路。
方法根据临床实际，健康受试者人数以1∶2的比例匹配，回顾性筛选符合入排标准的VP患者和年龄、性别、受教育程度与其相匹配的PD患者、健康志愿者，健康志愿者作为健康对照（healthy control，HC）组。收集一般临床资料及生化指标，评估患者临床症状，采集头颅MRI参数并对3组受试者的资料进行统计分析。
结果本研究纳入26例VP患者、26例PD患者及13例HC，与PD组相比，VP组的整体认知、精神状态更差：HAMA得分（P=0.025）更高，MMSE得分（P=0.001）、MoCA得分（P=0.008）更低；血管危险因素更多：有高血压病史（P=0.012）和卒中病史（P＜0.001）的患者比例更高；运动相关脑区白质受损更严重：WMH总分（P＜0.001）、深部白质高信号（deep white matter hyperintensities，DWMH）总分（P=0.001）、脑室旁周围白质高信号（periventricular hyperintensities，PVH）总分（P=0.002）、运动相关脑区PVH评分[额角帽状白质高信号评分（P=0.002）、侧脑室带状白质高信号评分（P=0.018）]、运动相关脑区DWMH评分[额叶深部白质高信号评分（P<0.001）、顶叶深部白质高信号评分（P=0.007）]、基底节白质高信号评分（P=0.002）、壳核白质高信号评分（P=0.029）更高，上述差异均具有统计学意义（P＜0.05）。
结论高血压病史、卒中病史和运动相关脑区白质损伤在VP发病机制中可能有重要作用。

关键词: 血管性帕金森综合征; 帕金森病; 临床特征; 脑白质高信号

CHEN Baixi, WANG Wanyi, ZHAN Cuijing, GAO Yuyuan, NIE Kun, ZHANG Yuhu, WANG Lijuan. Differences between Clinical Features and White Matter Hyperintensities between Vascular Parkinsonism and Parkinson′s Disease[J]. Chinese Journal of Stroke, 2023, 18(8): 859-866.

陈柏希, 王婉仪, 詹翠京, 高玉元, 聂坤, 张玉虎, 王丽娟. 血管性帕金森综合征与帕金森病的临床特征及脑白质高信号差异性研究[J]. 中国卒中杂志, 2023, 18(8): 859-866.

References

[1] GARNIER-CRUSSARD A，BOUGACHA S，WIRTH M，et al. White matter hyperintensity topography in Alzheimer’s disease and links to cognition[J]. Alzheimers Dement，2022，18（3）：422-433.
[2] KORCZYN A D. Vascular parkinsonism-characteristics，pathogenesis and treatment[J]. Nat Rev Neurol，2015，11（6）：319-326.
[3] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国血管性帕金森综合征诊断与治疗专家共识[J]. 中华神经科杂志，2017，50（5）：326-331.
Parkinson’s Disease & Movement Disorders Society of Chinese Society of Neurology，Parkinson’s Disease & Movement Disorders Society of Chinese Neurology Association. Chinese experts' consensus of diagnosis and treatment of vascular parkinsonism[J]. Chin J Neurol，2017，50（5）：326-331.
[4] 谭晓琳，任艳，李松柏，等. 弥散张量成像在血管性帕金森综合征诊断中的应用[J]. 中国医科大学学报，2016，45（4）：361-370.
TAN X L，REN Y，LI S B，et al. Application of diffusion tensor image in diagnosis of vascular parkinsonism[J]. J Chin Med Univ，2016，45（4）：361-370.
[5] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准（2016版）[J]. 中华神经科杂志，2016，49（4）：268-271.
Parkinson’s Disease & Movement Disorders Society of Chinese Society of Neurology，Parkinson’s Disease & Movement Disorders Society of Chinese Neurology Association. Diagnostic criteria of Parkinson’s disease in China（2016）[J]. Chin J Neurol，2016，49（4）：268-271.
[6] SINANI O，DADOULI K，NTELLAS P，et al. Association between white matter lesions and Parkinson’s disease：an impact on postural/gait difficulty phenotype and cognitive performance[J]. Neurol Res，2022，44（12）：1122-1131.
[7] 王婉怡. 血管性帕金森综合征患者认知障碍特点及其脑白质损害的初步研究[D]. 广州：南方医科大学，2020.
WANG W Y. A preliminary study of cognitive impairment and white matter damage in patients with vascular parkinsonism[D]. Guangzhou：Southern Medical University，2020.
[8] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南（第四版）[J]. 中华神经科杂志，2020，53（12）：973-986.
Chinese Society of Parkinson’s Disease and Movement Disorders，Parkinson’s Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association. Chinese guidelines for the treatment of Parkinson’s disease（fourth edition）[J]. Chin J Neurol，2020，53（12）：973-986.
[9] ŠARAC H，MARKELJEVIĆ J，ERDELJIĆ V，et al. Signal hyperintensities on brain magnetic resonance imaging in patients with primary Sjogren syndrome and frequent episodic tension-type headache：relation to platelet serotonin level and disease activity[J]. J Rheumatol，2013，40（8）：1360-1366.
[10] 郑茂凤，时晶，李婷，等. 血管性帕金森综合征的临床特征及诊治研究进展[J]. 中华脑血管病杂志（电子版），2022，16，（5）：347 -350.
ZHENG M F，SHI J，LI T，et al. The clinical characteristics，diagnosis and treatment of vascular Parkinsonism[J]. Chin J Cerebrovase Dis（Electronic Edition），2022，16，（5）：347 -350.
[11] KALRA S，GROSSET D G，BENAMER H T. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease：a systematic review[J]. Mov Disord，2010，25（2）：149-156.
[12] ZOU J，CHEN Z G，LIANG C Q，et al. Trefoil factor 3，cholinesterase and homocysteine：potential predictors for Parkinson’s disease dementia and vascular parkinsonism dementia in advanced stage[J]. Aging Dis，2018，9（1）：51-65.
[13] LI J，GU C Z，ZHU M，et al. Correlations between blood lipid，serum cystatin C，and homocysteine levels in patients with Parkinson’s disease[J]. Psychogeriatrics，2020，20（2）：180-188.
[14] TENG Z J，FENG J，LIU R H，et al. Cerebral small vessel disease mediates the association between homocysteine and cognitive function[J/OL]. Front Aging Neurosci，2022，14：868777[2023-04-11]. https://doi.org/10.3389/fnagi.2022.868777.
[15] RABELO N N，TELLES J P M，PIPEK L Z，et al. Homocysteine is associated with higher risks of ischemic stroke：a systematic review and meta-analysis[J/OL]. PLoS One，2022，17（10）：e0276087[2023-04-11]. https://doi.org/10.1371/journal.pone.0276087.
[16] JI Y F，LI X Y，TENG Z J，et al. Homocysteine is associated with the development of cerebral small vessel disease：retrospective analyses from neuroimaging and cognitive outcomes[J/OL]. J Stroke Cerebrovasc Dis，2020，29（12）：105393[2023-04-11]. https://doi.org/10.1016/j.jstrokecerebrovasdis.
[17] FITZGERALD P M，JANKOVIC J. Lower body parkinsonism：evidence for vascular etiology[J]. Mov Disord，1989，4（3）：249-260.
[18] 石松鑫，王大力，李弘，等. 血管性帕金森综合征与帕金森病认知功能的比较[J]. 中国卒中杂志，2022，17（4）：341-345.
SHI S X，WANG D L，LI H，et al. Comparison of cognitive function between vascular parkinsonism and Parkinson’s disease[J]. Chin J Stroke，2022，17（4）：341-345.
[19] SALSONE M，CALIGIURI M E，VESCIO V，et al. Microstructural changes of normal-appearing white matter in vascular parkinsonism[J/OL]. Parkinsonism Relat Disord，2019，63：60-65[2023-04-11]. https://doi.org/10.1016/j.parkreldis.2019.02.046.
[20] SOLE-GUARDIA G，CUSTERS E，DE LANGE A，et al. Association between hypertension and neurovascular inflammation in both normal-appearing white matter and white matter hyperintensities[J/OL]. Acta Neuropathol Commun，2023，11（1）：2[2023-04-11]. https://doi.org/10.1186/s40478-022-01497-3.
[21] CHEN H M，WAN H J，ZHANG M M，et al. Cerebral small vessel disease may worsen motor function，cognition，and mood in Parkinson’s disease[J/OL]. Parkinsonism Relat Disord，2021，83：86-92[2023-04-11]. https://doi.org/10.1016/j.parkreldis.2020.12.025.
[22] TODA K，IIJIMA M，KITAGAWA K. Periventricular white matter lesions influence gait functions in Parkinson’s disease[J]. Eur Neurol，2019，81（3/4）：120-127.
[23] NOVAK V，HAERTLE M，ZHAO P，et al. White matter hyperintensities and dynamics of postural control[J]. Magn Reson Imaging，2009，27（6）：752-759.
[24] RYU W S，WOO S H，SCHELLINGERHOUT D，et al. Grading and interpretation of white matter hyperintensities using statistical maps[J]. Stroke，2014，45（12）：3567-3575.
[25] BOHNEN N I，BOGAN C W，MÜLLER M L. Frontal and periventricular brain white matter lesions and cortical deafferentation of cholinergic and other neuromodulatory axonal projections[J]. Eur Neurol J，2009，1（1）：33-50.
[26] WAN Y，HU W J，GAN J，et al. Exploring the association between cerebral small-vessel diseases and motor symptoms in Parkinson’s disease[J/OL]. Brain Behav，2019，9（4）：e01219[2023-04-11]. https://doi.org/10.1002/brb3.1219.
[27] ALLART E，DEVANNE H，DELVAL A. Contribution of transcranial magnetic stimulation in assessing parietofrontal connectivity during gesture production in healthy individuals and brain-injured patients[J]. Neurophysiol Clin，2019，49（2）：115-123.
[28] ALMAIRAC F，HERBET G，MORITZ-GASSER S，et al. Parietal network underlying movement control：disturbances during subcortical electrostimulation[J]. Neurosurg Rev，2014，37（3）：513-517.
[29] 张欣，郭婷婷，王玉洁. 顶叶脑卒中与运动系统功能障碍[J]. 中华老年心脑血管病杂志，2019，21（8）：891-892.
ZHANG X，GUO T T，WANG Y J. Parietal stroke and motor system dysfunction[J]. Chin J Geriatr Heart Brain Ves Dis，2019，21（8）：891-892.
[30] MONTEMURRO N，ALIAGA N，GRAFF P，et al. New targets and new technologies in the treatment of Parkinson’s disease：a narrative review[J/OL]. Int J Environ Res Public Health，2022，19（14）：8799[2023-04-11]. https://doi.org/10.3390/ijerph19148799.
[31] VESELÝ B，ANTONINI A，REKTOR I. The contribution of white matter lesions to Parkinson’s disease motor and gait symptoms：a critical review of the literature[J]. J Neural Transm（Vienna），2016，123（3）：241-250.